HK Stocks Midday: Akeso Surges Over 14% to Lead Gains, HSI Falls 0.63%
nashnova research
The Hang Seng Index fell 0.63% to 24,486 at midday, but pharma stocks bucked the trend — Akeso surged over 14% after AstraZeneca committed a $2 billion strategic stake in its overseas partner, a top-tier endorsement that kept widening through the morning.
The index fell — so where did the money go?
The HSI shed 155 points to 24,486, down 0.63%; the Hang Seng Tech Index dropped 1.37%, with tech dragging harder.
Morning turnover hit HK$90.9 billion — capital was active, not sidelined. Two pockets attracted inflows: pharma and mainland property.
This means → the broad market was soft, but the structure was clear: sectors with a catalyst still rallied.
Why did Akeso jump over 14% in one session?
The catalyst: AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics, Akeso's overseas partner.
AstraZeneca also plans to advance ivonescimab — Akeso's core oncology drug — in combination trials with its own therapies. In plain terms = a global top-tier pharma company not only put up real cash but offered its own pipeline for combination studies — the highest level of clinical endorsement a biotech can receive.
Akeso's gain widened from roughly 10% at the open to over 14% by midday, leading the Hang Seng Biotech Index, the Innovative Drug Index, and the blue-chip board.
Why did Connect Biopharma rally over 9% on the same news?
AstraZeneca is leading clinical work combining ivonescimab with Sone-Ve — a CLDN18.2-targeting ADC drug for gastrointestinal cancers.
Sone-Ve, originally called CMG901, was developed by KYM, a joint venture between Connect Biopharma (康諾亞-B) and LP Biopharma. Connect Biopharma holds 70% of the JV.
This means → AstraZeneca's deal radiates beyond Akeso alone — Connect Biopharma, as the drug's originator, benefits directly.
Why are property and optical-comms stocks also rising?
Mainland property extended gains: Greentown China rose over 8% and Jinghui Holdings over 7%. The catalyst was a State Council executive meeting signaling new policies to stabilize the property market; brokers expect core cities to recover first.
Optical-comms and PCB names rebounded: YOFC gained 5% and Guanghe Technology 6%. Citi and Jefferies both said the relevant U.S. legislation would have limited impact on the sector, while AI compute expansion continues to drive demand.
In plain terms = property is riding policy expectations; optical-comms is riding reassurance from foreign brokers — different logic, but both backed by concrete catalysts.
How did the IPOs and other movers perform?
Four new listings diverged: Kingwang Electronics up 9% and Benmo Technology up over 4%; Roobotech down 5.5% and Tongcheng Advanced Materials down over 8%.
Other standouts: Lead Intelligent surged over 8% (seven ministries published a solid-state battery development plan for 2026–2030); HanTianTianCheng rose over 7% (strong SiC supply-chain demand); Dajin Heavy Industry gained over 5% (partnered with Norway's Ulstein on next-gen offshore wind installation vessels).
On the downside, Shein-W fell over 10% to a new low — adjusted net profit halved in H1 as both the U.S. and European markets weakened. It was among the worst-performing blue chips at midday.
What to watch in the afternoon session?
Whether Akeso can hold its 14%+ gain into the close is the key litmus test for the pharma sector's continued leadership.
This reflects a bigger question: in a soft broad market, how far can a single-catalyst sector rally run? The answer depends on whether funds take profits or add positions into the close.
Whether mainland-property stocks can convert policy headlines into actual turnover is equally worth watching in the afternoon.
市场有风险，内容仅供研究参考，不构成投资建议。